MDBP, 1-(3,4-Methylenedioxybenzyl)piperazine (MDBZP, piperonylpiperazine) is a chemical compound of the piperazine chemical class related to benzylpiperazine (BZP). MDBZP has been sold as a designer drug and has even been found as an ingredient in street Ecstasy pills.
MDBZP has not been used in therapy. As described elsewhere, fipexide was a nootropic used in the treatment of cognitive disorders (Bompani and Scali, 1986) but was later withdrawn due to its adverse effects (particularly hepatic toxicity).
Denmark, Japan, Mongolia, and Tuvalu reported that MDBP is controlled under legislation that is intended to regulate the availability of substances of abuse.In Japan, MDBP is controlled as designated substances under the Pharmaceutical Affairs Law in Japan since January 2008.Besides Mongolia, there are no other countries who have tracked illicit activities involving the substance. They reported clandestine manufacturing and also smuggling is reported. There are no reports on the quantity of the seizures.
Of the responded countries only Mongolia authorized MDBP as a medical or veterinary product and the USA legitimated TFMPP for technical use only. There are no countries where another legitimate use is reported.The substance is granted market admission since 1995 in Mongolia under the brand name “KRKA” and reported its “indication” to be “Fluphenazine deconcate”, and also off-label use as “Moditen depo”. The dosage is 25 mg/ml and it is in ampoule form. 3 countries indicated that they import the substance. These are Brunei, Mongolia, and Tuvalu.
As for BZP and TFMPP, MDBZP use appears to be associated with situations similar to that of “Ecstasy”, or with users who are seeking effects similar to “Ecstasy” (MDMA in particular) and therefore instances of misuse, abuse and dependence would be limited to such individuals rather than the general population (DEA, 2004). The mode of use could involve the combinational use (intentionally or unintentionally) of other piperazine-derivatives (e.g. BZP) or other substances. No fatal or non-fatal intoxications of MDBZP (with or without other substances) have been reported.